SAN DIEGO, Sept. 21, 2007 (PRIME NEWSWIRE) -- MicroIslet, Inc. (OTCBB:MIIS), a development-stage biotechnology company with patented and proprietary technologies focused on transplantation therapy for people with insulin-dependent diabetes, today announced that an existing investor has agreed to lend the Company $1 million in cash.
